Get 50% OFF This Monsoon!
Vimta Labs
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc.
The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994.
In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia.
During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials.
The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005.
During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006.
During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.
Vimta Labs share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Vimta Labs indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Vimta Labs is valued compared to its competitors.
Vimta Labs PE ratio helps investors understand what is the market value of each stock compared to Vimta Labs 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Vimta Labs evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Vimta Labs generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Vimta Labs in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Vimta Labs shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Vimta Labs compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Vimta Labs over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Vimta Labs helps investors get an insight into when they can enter or exit the stock. Key components of Vimta Labs Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Vimta Labs shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Vimta Labs ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Vimta Labs provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Vimta Labs highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Vimta Labs .
The balance sheet presents a snapshot of Vimta Labs ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App